FDA seeks to drop suicide risk warnings on GLP-1 weight-loss drugs
TL;DR Summary
The FDA asked manufacturers of GLP-1 weight-loss drugs (Wegovy, Zepbound, Saxenda) to remove label warnings about suicidal thoughts after reviewing 91 trials with 107,910 patients and finding no evidence of increased suicidal thoughts, behavior, or other psychiatric effects versus placebo, though earlier data could not completely rule out a small risk.
- FDA requests removal of suicide warnings from weight-loss drugs CNBC
- US FDA requests removal of suicide warnings from weight-loss drugs CNN
- US FDA requests removal of suicide warnings from weight-loss drug labels Reuters
- FDA Says to Drop Suicide Warning From GLP-1 Drug Labels MedPage Today
- FDA asks popular weight loss medication makers to remove suicide risk warning kare11.com
Reading Insights
Total Reads
0
Unique Readers
7
Time Saved
1 min
vs 2 min read
Condensed
80%
251 → 51 words
Want the full story? Read the original article
Read on CNBC